NASHUA, NH and SAN DIEGO, CA, 25 September 2017 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that external researchers will present new clinical data supporting the use of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of nonmelanoma skin cancer (NMSC) and early-stage breast cancer during the 2017 American Society for Radiation Oncology (ASTRO) meeting at the San Diego Convention Center in San Diego, CA from September 24-27. iCAD will also host additional presentations and a series of peer-to-peer discussion opportunities with leading eBx experts at its booth (#3139).

"We look forward to the presentation of these compelling new clinical data by leading external researchers that significantly reinforce the benefits that the Xoft System delivers to patients and physicians in the treatment of both early-stage breast cancer and nonmelanoma skin cancer," said Ken Ferry, CEO of iCAD. "Our technology is proven to be safe and effective in appropriate patients, while offering the opportunity to treat a range of cancers using one versatile, integrated system. iCAD remains committed to providing innovative, leading-edge radiation therapies that empower physicians with full confidence to precisely and effectively treat cancer."

In an oral presentation, Rakesh Patel, MD, radiation oncologist at Precision Cancer Specialists, will review results from a study published in the Journal of Contemporary Brachytherapy comparing the use of the Xoft System and Mohs micrographic surgery for the treatment of NMSC.
"While Mohs surgery is considered the standard of care for NMSC, Xoft skin eBx represents an important option for many patients that can target the radiation dose directly to the cancerous site in a painless, non-invasive procedure," said Dr. Patel. "We are excited to present these data, which add to a growing body of evidence indicating that eBx offers comparable results to Mohs surgery in appropriately selected early-stage NMSC patients."

Nicholas Flores, MD, director of radiation oncology at Arizona Dermatology, will also present data from a study of the treatment of peri-ocular NMSC using the Xoft System. From 2013 to 2016, Dr. Flores and fellow researchers treated 86 patients with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the eyelid with Xoft skin eBx. Results showed a 99 percent local control rate at two years post-treatment and no reported cases of side effects, such as long-term vision changes, dry eye, corneal injury, or retinitis.

Rad Oncology Homepage